CClinicalTrials.gg
Active, not recruitingNCT06724146Updated Dec 9, 2024

Combined Treatment Sofwave and Pure Impact to Strength and Tone Muscles and Improve Lax Skin Appearance

An interventional study of Sofwave and Pure Impact in Skin Lax and Muscle Strength, sponsored by Sofwave Medical LTD. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Sofwave Medical LTD · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2024, registered Dec 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
25 Years to 70 Years
Sex
All
01

Study summary

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study.

Read the detailed description

Eligible patients will receive combined treatment on both upper arms, included 1 or 2 SofWave treatments and 4 Pure Impact treatments. At the first session (Visit 1), subjects undergo SofWave treatment, and may undergo Pure Impact treatment also at the same visit. If conducting the two procedures on the same day, Pure Impact shall be applied before SofWave. If the procedures are done in separate visits, schedule the Pure Impact 2-7 days after the SofWave procedure. If the two treatments are conducted on the same day, then the second Pure Impact session will be 7-10 days after; similarly, the third and fourth Pure Impact sessions will be performed 7-10 days apart following the previous session. The last (fourth) Pure Impact treatment may occur on the same day or after the optional second SofWave treatment. If conducting the two procedures on the same day, Pure Impact shall be applied before SofWave. If the procedures are done in separate visits, schedule the SofWave 2-7 days after the fourth Pure Impact procedure.

All patients will return to the clinic for two follow-up visits at 4±1 weeks and at 12±2 weeks post last treatment (FU1 and FU2).

02

Conditions studied

  • Skin Lax and Muscle Strength

Browse trials for

Keywords

  • Upper arm
  • skin laxity
  • muscle tone
  • muscle strength
  • muscle firm
03

In context

Cutis Laxa

147 studies on the registry are indexed under Cutis Laxa; 35 are open to participants now.

This study's planned enrollment of 70 is above the median of 30 across 129 interventional studies indexed under Cutis Laxa.

Browse Cutis Laxa studies →

Lead sponsor

Sofwave Medical LTD is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Male or female subjects ≥ 25 years of age and ≤ 70 years of age.
  2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
  3. Desire to undergo treatments on upper arms for skin lax and for strength and tone muscles.
  4. Subject has clearly visible lax skin on the upper arm, which in the investigator's opinion, may benefit from the treatment.
  5. Subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the study.
  6. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
  7. Willing to have research photos taken of treatment areas.
  8. Subject agrees not to undergo any other upper arm skin lax treatments for a period of 3 months following SofWave and Pure Impact treatments.
  9. Able to understand and provide written Informed Consent.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
  2. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, open wounds etc.) in the treatment area.
  3. Medical disorder that would hinder the wound healing or immune response (such as blood disorder) including but not limited to arterial circulation disorders in lower limbs, inflammatory disease, etc.
  4. Known allergy to lidocaine or epinephrine.
  5. Active malignancy or history of malignancy in the past 5 years.
  6. Suffering from significant concurrent illness, such as cardiac disorders, sensory disturbances, diabetes (type I or II), epilepsy, lupus, porphyria, pertinent neurological disorders, uncontrolled hypertension, or liver or kidney disease (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
  7. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
  8. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
  9. History of significant lymphatic drainage problems.
  10. Currently a heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
  11. History of chronic drug or alcohol abuse.
  12. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
  13. BMI>30kg/m2
  14. Non-stable weight nominally ±5% in the past month.
  15. Active implanted device such as a pacemaker, defibrillator, drug delivery system or any other metallic or electric implant anywhere in the body.
  16. Permanent implant in the treated area such as metal plates, screws and metal piercing, silicone implants or an injected chemical substance, unless deep enough in the periosteal plane.
  17. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
  18. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.).
  19. History of prior surgery in the upper arms.
  20. Excessive subcutaneous fat on the upper arms.
  21. Severe solar elastosis on the intended to treat area.
  22. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising.
  23. Tattoo or former tattoo at or near treatment area.
  24. Muscle atrophy.
  25. Need for muscle rehabilitation.
  26. Persistent pain at the treated area.
  27. Any sensitivity for hydrogel (Pure Impact electrodes pads are made of hydrogel).
  28. History of ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peeling within the past 12 months on the intended to treat area.
  29. Inability to understand the protocol or to give informed consent.
  30. Unable or unwilling to comply with the study requirements and procedures.
  31. Currently enrolled in a clinical study of any other unapproved investigational drug or device.
  32. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Lax Tissue and Muscles

    Device: Sofwave and Pure Impact

Interventions

  • DeviceSofwave and Pure Impact

    The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues. Pure Impact is an EMS module. This module is wirelessly connected to and controlled by the SofWave console. It functions independently from the existing ultrasound module. Pure Impact generates electrical impulses, which are delivered through electrodes on the skin in direct proximity to the muscles to be stimulated.

    Also known as: SUPERB

06

What researchers measure

Primary outcomes

  1. Improvement in the appearance of lax skin

    Rate of improvement in the appearance of lax skin and in the strength and tone muscles in the upper arms following Sofwave and Pure Impact combined treatment based on Global Aesthetic Improvement Scale, as evaluated by independent masked reviewers.

    Time frame: 3 months post treatment follow-up visit

07

Study locations

1 site
  • Tennessee Clinical Research Center
    Nashville, Tennessee 37215, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06724146
Lead sponsor
Sofwave Medical LTD
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Aug 5, 2024
Primary completion
Oct 1, 2026 (estimated)
Completion
Nov 1, 2026 (estimated)
Last update
Dec 9, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion